<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Excessive activity of hepatic atypical protein kinase (aPKC) is proposed to play a critical role in mediating <z:chebi fb="23" ids="18059">lipid</z:chebi> and carbohydrate abnormalities in <z:hpo ids='HP_0001513'>obesity</z:hpo>, the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In previous studies of <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, adenoviral-mediated expression of kinase-inactive aPKC rapidly reversed or markedly improved most if not <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we examined effects of 2 newly developed small-molecule PKC-ι/λ inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>We used the mouse model of heterozygous muscle-specific knockout of PKC-λ, in which partial deficiency of muscle PKC-λ impairs <z:chebi fb="105" ids="17234">glucose</z:chebi> transport in muscle and thereby causes <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> and <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo>, which, via hepatic aPKC activation, leads to abdominal <z:hpo ids='HP_0001513'>obesity</z:hpo>, hepatosteatosis, <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo>, and <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>One inhibitor, <z:chebi fb="0" ids="16069">1H-imidazole</z:chebi>-4-<z:chebi fb="0" ids="23004,37622">carboxamide</z:chebi>, 5-amino-1-[2,3-dihydroxy-4-[(<z:chebi fb="0" ids="32958">phosphonooxy</z:chebi>)<z:chebi fb="36" ids="29309">methyl</z:chebi>]<z:chebi fb="0" ids="52880">cyclopentyl</z:chebi>-[1R-(1a,2b,3b,4a)], binds to the substrate-binding site of PKC-λ/ι, but not other PKCs </plain></SENT>
<SENT sid="5" pm="."><plain>The other inhibitor, <z:chebi fb="0" ids="38722">aurothiomalate</z:chebi>, binds to <z:chebi fb="0" ids="32460">cysteine residues</z:chebi> in the PB1-binding domains of aPKC-λ/ι/ζ and inhibits scaffolding </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with either inhibitor for 7 days inhibited aPKC, but not Akt, in liver and concomitantly improved insulin signaling to Akt and aPKC in muscle and adipocytes </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, both inhibitors diminished excessive expression of hepatic, aPKC-dependent lipogenic, proinflammatory, and gluconeogenic factors; and this was accompanied by reversal or marked improvements in <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo>, abdominal <z:hpo ids='HP_0001513'>obesity</z:hpo>, hepatosteatosis, <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo>, and <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings highlight the pathogenetic importance of insulin signaling to hepatic PKC-ι in <z:hpo ids='HP_0001513'>obesity</z:hpo>, the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and suggest that <z:chebi fb="0" ids="16069">1H-imidazole</z:chebi>-4-<z:chebi fb="0" ids="23004,37622">carboxamide</z:chebi>, 5-amino-1-[2,3-dihydroxy-4-[(<z:chebi fb="0" ids="32958">phosphonooxy</z:chebi>)<z:chebi fb="36" ids="29309">methyl</z:chebi>]<z:chebi fb="0" ids="52880">cyclopentyl</z:chebi>-[1R-(1a,2b,3b,4a)] and <z:chebi fb="0" ids="38722">aurothiomalate</z:chebi> or similar agents that selectively inhibit hepatic aPKC may be useful treatments </plain></SENT>
</text></document>